A randomized, open-label, phase 3 trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic Non-Small Cell Lung Cancer (NSCLC) and secondary resistance to Immune Checkpoint Inhibitor (ICI) - ARTEMIA study

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509340-10-00

Acronym

OSE2101C302

Enrollment

318

Registered

2024-09-03

Start date

2024-10-29

Completion date

Unknown

Last updated

2026-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with HLA-A2 positive phenotype and metastatic Non-Small Cell Lung Cancer.

Brief summary

OS defined as time from randomization to death of any cause

Interventions

DRUGDOCETAXEL

DRUGTEDOPI

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
OS defined as time from randomization to death of any cause	—

Countries

Belgium, France, Germany, Greece, Hungary, Italy, Netherlands, Poland, Portugal, Romania, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026